103185-78-0

Basic information

• Product Name: SERATRODAST
• Synonyms: Benzeneoctanoic acid, η-(2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-
• CAS NO: 103185-78-0
• Molecular Formula: C22H26O4
• Molecular Weight: 354.443
• Product Categories: Seratrodast
• Mol File: 103185-78-0.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: SERATRODAST(CAS DataBase Reference)
• NIST Chemistry Reference: SERATRODAST(103185-78-0)
• EPA Substance Registry System: SERATRODAST(103185-78-0)

Safety Data

• Hazardous Substances Data: 103185-78-0(Hazardous Substances Data)

Upstream product

• 103187-11-7 8-acetoxy-8-phenyloctanoic acid 
• 700-13-0 Trimethylhydroquinone 
• 109-63-7 boron trifluoride diethyl etherate 
• 71-43-2 benzene 
• 103187-10-6 8-hydroxy-8-phenyloctanoic acid 
• 14113-01-0 Ethyl hydrogen suberate 

Relevant articles and documents

Quinone derivatives, their production and use

Quinone derivatives of the general formula: STR1 (wherein R1 and R2 are the same or different, and independently are a hydrogen atom or a methyl or methoxy group, or R1 and R2 combine with each other to represent --CH=CH--CH=CH--R3 is a hydrogen atom or a methyl group; R4 is an aliphatic, aromatic or heterocyclic group which may be substituted; R5 is a methyl or methoxy group, a hydroxymethyl group which may be substituted or a carboxyl group which may be esterified or amidated; Z is a group represented by --C=C--, --CH=CH--, STR2 n is an integer of 0 to 10; m is an integer of 0 to 3; k is an integer of 0 to 5, provided, however, that in the case of m being 2 or 3, Z and k can vary arbitrarily within the bracketed repeating units) are novel compounds, possess metabolism ameliorating action for polyunsaturated fatty acids, particularly production inhibitory activity of lipid peroxides (antioxidant activity), thromboxane A2 receptor antagonism, or production inhibitory activity of 5-lipoxygenase metabolites in mammals, and of use as drugs, such as antiasthmatic, antiallergic agent and cerebral-circulatory metabolism ameliorating agent.

Quinones. 4. Novel eicosanoid antagonists: Synthesis and pharmacological evaluation

A new series of ω-phenyl-ω-quinonylalkanoic acids and related compounds was synthesized. The compounds were tested for their inhibitory effects on U-44069-induced contraction of the rabbit aorta. (±)-7-(3,5,6-Trimethyl-1,4-benzoquinon-2-yl)-7-phenylheptanoic acid (4d) (AA-2414) with pA2 value of 8.28 was one of the most potent compounds. Compound 4d inhibited U-46619-induced contraction of the guinea pig lung (pA2 = 8.29) and U-44069-induced aggregation of the guinea pig platelet (IC50 = 3.5 x 10-7 M). Compound 4d displaced the binding of [3H]U-46619 to guinea pig platelets (IC50 = 7.4 x 10-9 M). Compound 4d also showed very potent inhibitory effects with an MED of 0.3 mg/kg (po) on U-46619-, LTD4-, PAF-, or IgG1-induced bronchoconstriction in guinea pigs. The enantiomers of 4d were prepared. The R-(+) isomer 8a was active in both in vitro and in vivo tests, but the S-(-) isomer 8b was much less active. We concluded that the antiasthmatic effects of 4d were based mainly on the TXA2 receptor antagonistic action. In addition, compound 4d showed potent inhibitory effects on PGD2-, PGF(2α)-, and 11-epi-PGF(2α)-induced contraction of the guinea pig tracheal strips. The diverse inhibitory effects might be expressed in terms of eicosanoid-antagonistic activity.